Adverse drug reactions to biologics
- 26 May 2010
- journal article
- review article
- Published by Wiley in JDDG: Journal der Deutschen Dermatologischen Gesellschaft
- Vol. 8 (6), 411-426
- https://doi.org/10.1111/j.1610-0387.2010.07339.x
Abstract
The use of biologics has rapidly expanded since the introduction of the first diagnostic antibodies; they are now widely employed in oncology, autoimmune disorders, inflammatory diseases and transplantation medicine. Their widespread use has resulted in an increase in adverse drug reactions. Adverse effects result from both direct pharmacological actions and immunological actions, as well as through induction of a specific immune response. The nomenclature, particularly of the monoclonal antibodies, identifies the target structure and organ as well as the species of origin, which then helps predict their effects and antigenic properties. Depending on the extent of foreign protein, anti-allotypic or anti-idiotypic antibodies with or without neutralizing properties may be induced. Adverse drug reactions from biologics often depend on the target and may be explained by activation or inhibition of particular cytokine pathways. Adverse drug reactions are classified by their pathomechanism, which enhances understanding of the pathogenesis and facilitates both allergologic diagnostic measures and planning of premedication in future treatments. This review emphasizes immunostimulatory and hypersensitivity reactionsKeywords
This publication has 54 references indexed in Scilit:
- Anaphylactic Reaction to Anakinra in a Rheumatoid Arthritis Patient Intolerant to Multiple Nonbiologic and Biologic Disease-Modifying Antirheumatic DrugsAnnals of Pharmacotherapy, 2009
- Fatal Toxic Epidermal Necrolysis Associated With Cetuximab in a Patient With Colon CancerJournal of Clinical Oncology, 2008
- Cetuximab-Induced Anaphylaxis and IgE Specific for Galactose-α-1,3-GalactoseThe New England Journal of Medicine, 2008
- Hypersensitivity reactions to biological agents with special emphasis on tumor necrosis factor-α antagonistsCurrent Opinion in Allergy and Clinical Immunology, 2007
- Cost-effectiveness of psoriasis therapy with etanercept in GermanyJDDG: Journal der Deutschen Dermatologischen Gesellschaft, 2007
- The use of infliximab in dermatologyJDDG: Journal der Deutschen Dermatologischen Gesellschaft, 2007
- Management and Preparedness for Infusion and Hypersensitivity ReactionsThe Oncologist, 2007
- Scientific and regulatory considerations on the immunogenicity of biologicsTrends in Biotechnology, 2006
- Accoutumance médicamenteuse à l’infliximab dans la maladie de CrohnRevue des Maladies Respiratoires, 2005
- A patient's reaction to infliximabAnnals of Allergy, Asthma & Immunology, 2003